INBRAIN Neuroelectronics, a Barcelona-based brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, has announced a strategic collaboration with Microsoft to advance real-time precision neurology through agentic artificial intelligence. The partnership aims to integrate Microsoft’s Azure AI infrastructure—including time-series large language models and advanced data analytics—into INBRAIN’s intelligent neural platform, enabling continuous learning and adaptive responses to individual patient neural signals. At the core of the collaboration is the goal of creating autonomous, personalized brain-computer interfaces capable of closed-loop interventions for neurological disorders such as Parkinson’s disease, epilepsy, psychiatric conditions, and memory impairments. Agentic AI, which operates autonomously by interpreting real-time data and taking actions without constant human input, will allow the system to not only decode neural activity but also dynamically modulate it in response to changing brain states. This represents a significant leap beyond traditional BCI systems, which typically rely on static or manually adjusted parameters. Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics, emphasized the transformative potential of the partnership: “Our vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI.” She described the future goal as making the nervous system a “body OS” that can be understood and responded to in real time by AI, enabling truly adaptive and intelligent neurotherapeutics. Microsoft’s involvement brings powerful cloud computing, scalable data infrastructure, and expertise in responsible AI development. Clare Barclay, President of Enterprise and Industry, EMEA at Microsoft, highlighted the significance of the collaboration: “This collaboration highlights the next frontier of AI. INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide.” INBRAIN’s platform is built on graphene, a single layer of carbon atoms renowned for its exceptional electrical conductivity, biocompatibility, and precision. These properties make it ideal for long-term, high-fidelity neural recording and stimulation. By combining graphene-based hardware with agentic AI, INBRAIN aims to develop a new class of therapeutics that can deliver data-driven, real-time modulation of neural circuits—adapting treatment as a patient’s condition evolves. The collaboration builds on Microsoft’s broader investments in healthcare AI, cognitive modeling, and ethical data architecture, with a strong focus on patient privacy and responsible innovation. The partnership also complements INBRAIN’s existing strategic alliances, including with Merck KGaA and its subsidiary INNERVIA Bioelectronics, which is expanding neurotechnology applications to peripheral nerves and systemic diseases. While the initial phase focuses on advancing the AI-driven platform for central nervous system disorders, the long-term vision includes extending these capabilities to treat a wide range of neurological and even systemic conditions. The integration of AI with bioelectronics could redefine how chronic neurological diseases are managed, shifting from reactive to proactive, personalized care. This collaboration marks a pivotal moment in the convergence of neuroscience, materials science, and artificial intelligence. As INBRAIN and Microsoft push the boundaries of what’s possible, their work could pave the way for a new era of intelligent, adaptive neurotherapeutics—where AI doesn’t just assist clinicians but actively participates in real-time healing.